Standard-of-care (SOC) efficacy in oncology, neurology, and cardiology is increasingly limited not by target engagement, but by bioenergetic gating in the host tissue. When cellular phosphorylation potential (ΔG'ATP) falls below critical thresholds (~52 kJ/mol), signaling pathways enter a functional brownout: receptors bind, kinases phosphorylate, but downstream execution fails. This thermodynamic constraint explains response ceilings that persist despite decades of target optimization.
Senovia Biosciences is developing Metabolic State Actuators: drug-like substrates engineered to restore ΔG'ATP with the precision, titratability, and controlled exposure profiles required for pharmaceutical combination regimens. The platform operates orthogonally to SOC: rather than competing with receptor ligands, it restores the thermodynamic capacity that enables them to execute.
The ability of metabolic state correction to produce recovery-level outcomes is supported by independent, peer-reviewed datasets across multiple organ systems (Table 1), including a +40% increase in cardiac output in human heart failure (Nielsen et al., Circulation 2019), complete response induction in checkpoint-resistant tumors (Ferrere et al., JCI Insight 2021), and a Cochrane-validated risk ratio of 5.80 for seizure reduction in drug-resistant epilepsy (4 RCTs, n=385).
Drug discovery has historically evolved to address whichever bottleneck limits efficacy in each era. Receptor pharmacology yielded to pathway pharmacology when compensatory feedback loops undermined single-target agents. Pathway pharmacology yielded to immuno-pharmacology when mutational resistance overwhelmed cascade-level control. The current generation of immunotherapies now faces its own ceiling: host tissue metabolic exhaustion.
| Era | Intervention Level | Limiting Constraint |
|---|---|---|
| Receptor Pharmacology | Single targets (beta-blockers, SSRIs) | Compensatory feedback loops |
| Pathway Pharmacology | Cascades (kinase inhibitors, mTOR) | Mutation-driven resistance and heterogeneity |
| Immuno-Pharmacology | System recruitment (checkpoint inhibitors) | Host tissue metabolic exhaustion |
| Metabolic State Medicine | Bioenergetic driving force (ΔG'ATP) | Restores thermodynamic substrate for bound-target execution |
The common failure mode is thermodynamic. In the tumor microenvironment, CD8+ T-cells recruited by checkpoint blockade cannot sustain cytotoxic function in nutrient-depleted tissue.1,2 In neurodegeneration, synaptic repair mechanisms require ATP-dependent processes that glucose hypometabolic neurons cannot power.3 In heart failure, cardiomyocytes oxidizing fatty acids at low efficiency cannot generate the hydraulic work demanded by afterload.4 In each case, the target is engaged. The energy to execute is absent.
Metabolic State Medicine does not compete with these interventions. It operates in a complementary, orthogonal dimension: restoring the thermodynamic substrate on which all downstream signaling depends.
The following datasets are selected for effect size, model quality, and direct relevance to active pharmaceutical programs. All citations are to peer-reviewed, indexed publications.
| Indication | Model / Context | SOC Baseline | Metabolic Actuation Outcome |
|---|---|---|---|
| Heart Failure | Human HFrEF (n=16, RCT) | Baseline CO: 4.8 L/min | +2.0 L/min increase (40%, p<0.001) in cardiac output vs. placebo4 |
| Oncology | RET melanoma (PD-1 resistant) | Anti-PD-1 alone: minimal inhibition | 3HB + anti-PD-1 induced complete responses in resistant subset (>70% CR)2 |
| Epilepsy | Drug-resistant childhood epilepsy (4 RCTs, n=385) | Standard anticonvulsants: refractory | 38% responders (>50% reduction) vs. 6% control; RR 5.805,6 |
| Neurodegeneration | 103 preclinical studies; multiple human RCTs | Anti-amyloid Abs: modest slowing | 60% show cognitive improvement (meta-analysis of 103 preclinical studies); human dose-response confirmed (r=0.45, p=0.04)3,7 |
| Autoimmunity | EAE (interventional, post-onset) | Fingolimod: partial stabilization | Near-complete recovery of motor/visual function after symptom onset8 |
| Infectious Disease / AMR | Gram-negative sepsis (murine) | Last-resort antibiotics failing | Fasting-induced ketogenesis sensitizes Gram-negatives to antibiotics; survival rescue in murine sepsis9 |
The mechanism of ketogenic actuation is well-established. The historical failure has been delivery. Dietary ketosis is adherence-limited, metabolically imprecise (variable PK), and achieves exposure below 1.0 mM in most subjects, making it incompatible with rigorous clinical combination protocols. First-generation ketone esters and salts produce transient spikes followed by rapid clearance, insufficient for sustained pathway engagement.
Senovia's platform resolves this gap by engineering controlled-exposure metabolic actuation: oral, titratable substrates that maintain blood concentrations above therapeutic thresholds for clinically relevant durations. This converts a validated biological state into a pharmaceutical tool compatible with combination study design.
Seven programs address distinct manifestations of bioenergetic constraint. Each leverages the common mechanism of metabolic state actuation while targeting indication-specific pathophysiology.
Metabolic adjuvant to existing checkpoint inhibitors. In PD-1-resistant RET/RENCA models, intermittent 3HB + anti-PD-1 induced complete responses and durable survival extension. Strategy: expand label claims of existing IO assets by converting non-responders.2
Scientific brief →Cognitive rescue via bioenergetic restoration. Metabolic correction in APP/PS1 models restored cognitive and synaptic function to near wild-type levels via IFITM3/ROS/cytokine pathway modulation. Behavioral recovery observed independent of amyloid burden reduction.7
Scientific brief →Pharmaceutical ketosis replacing dietary restriction. Cochrane meta-analysis (4 RCTs, n=385): RR 5.80 for >50% seizure reduction. Neal 2008 RCT: 38% responders vs. 6% control. Seizure freedom 10 to 32% in DEEs, up to 54% in Doose syndrome. Orphan + PRV pathway in rare epilepsies.5,6
Scientific brief →Metabolic inotropy: increased hydraulic work efficiency without the oxygen penalty of catecholamines. Anchored by human RCT data showing +2.0 L/min cardiac output increase (p<0.001) with maintained myocardial efficiency.4
Scientific brief →Interventional metabolic rescue after symptom onset. Ketogenic intervention produced near-complete recovery of motor and visual function in preclinical EAE demyelination models. Recovery-grade data, not neuroprotection.8
Scientific brief →Metabolic state actuation for treatment-resistant mood and psychotic disorders. Corpus analysis of 1,765 publications identifies convergent evidence across bipolar depression, schizophrenia, and alcohol use disorder. Case-series data shows 46% PANSS reduction in treatment-resistant inpatientsDanan 2022; complete PHQ-9 remission in treatment-resistant depression.Laurent 2025
Scientific brief →Antibiotic potentiation via acetoacetate-mediated membrane permeability. Primary evidence supports Gram-negative sensitization (Cui et al., Cell Metab 2025). Broader pathogen classes unproven. Hypothesis-stage program.9
Scientific brief →The convergence of six independent cardiac RCTs (2019-2024), a Cochrane meta-analysis validating RR 5.80 in drug-resistant epilepsy, and 2025 landmark publications in Cell Metabolism and Nature Metabolism has moved ketone biology from nutritional observation to pharmaceutical substrate with human proof-of-concept. The historical barrier was delivery: dietary ketosis is non-titratable, adherence-limited, and pharmacologically imprecise. That barrier is now an engineering problem with a defined solution. No competing pharmaceutical ketone program has entered clinical development.
For diligence materials, scientific discussion, or partnership inquiries: joel@senoviabiosciences.com
We are seeking pharma partners with IO, CNS, or cardiovascular assets to run proof-of-concept combination studies where metabolic state actuation may amplify response rates or circumvent resistance mechanisms.